Amneal Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
AMRX$21.28+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $282,029 | $110,552 |
| Restricted cash | 28,842 | 7,868 |
| Trade accounts receivable, net | 895,143 | 775,731 |
| Inventories | 606,302 | 612,454 |
| Prepaid expenses and other current assets | 98,395 | 80,717 |
| Related party receivables | 470 | 484 |
| Total current assets | 1,911,181 | 1,587,806 |
| Property, plant and equipment, net | 442,950 | 424,908 |
| Goodwill | 595,470 | 597,436 |
| Intangible assets, net | 563,498 | 732,377 |
| Operating lease right-of-use assets | 38,832 | 31,388 |
| Operating lease right-of-use assets - related party | 15,216 | 10,964 |
| Financing lease right-of-use assets | 53,328 | 56,433 |
| Other assets | 57,805 | 60,133 |
| Total assets | $3,678,280 | $3,501,445 |
| Liabilities and Stockholders’ Deficiency | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $761,316 | $735,450 |
| Current portion of liabilities for legal matters | 43,256 | 31,755 |
| Revolving credit facility | — | 100,000 |
| Current portion of long-term debt, net | 6,761 | 224,213 |
| Current portion of operating lease liabilities | 8,668 | 9,435 |
| Current portion of operating lease liabilities - related party | 2,705 | 3,396 |
| Current portion of financing lease liabilities | 3,442 | 3,211 |
| Related party payables - short term | 55,485 | 22,311 |
| Total current liabilities | 881,633 | 1,129,771 |
| Long-term debt, net | 2,565,115 | 2,161,790 |
| Operating lease liabilities | 33,233 | 24,814 |
| Operating lease liabilities - related party | 14,195 | 9,391 |
| Financing lease liabilities | 54,927 | 56,889 |
| Related party payable - long term | 19,132 | 50,900 |
| Liabilities for legal matters - long term | 71,819 | 85,479 |
| Other long-term liabilities | 32,263 | 26,949 |
| Total long-term liabilities | 2,790,684 | 2,416,212 |
| Commitments and contingencies (Notes 4, 19 and 22) | ||
| Redeemable non-controlling interests | 77,292 | 64,974 |
| Stockholders’ Deficiency: | ||
| Preferred stock, $0.01 par value, 2,000 shares authorized at December 31, 2025 and 2024; none issued at both December 31, 2025 and 2024 | — | — |
| Class A common stock, $0.01 par value, 900,000 shares authorized at both December 31, 2025 and 2024; 314,565 and 309,881 shares issued at December 31, 2025 and 2024, respectively | 3,146 | 3,099 |
| Class B common stock, $0.01 par value, 300,000 shares authorized at December 31, 2025 and 2024; none issued at December 31, 2025 and 2024 | — | — |
| Additional paid-in capital | 571,794 | 560,206 |
| Stockholders’ accumulated deficit | (535,005) | (607,062) |
| Accumulated other comprehensive loss | (110,729) | (65,510) |
| Total Amneal Pharmaceuticals, Inc. stockholders’ deficiency | (70,794) | (109,267) |
| Non-controlling interests | (535) | (245) |
| Total stockholders’ deficiency | (71,329) | (109,512) |
| Total liabilities and stockholders’ deficiency | $3,678,280 | $3,501,445 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.